Ctrl Worx Watch List › Company

Sigyn Therapeutics, Inc. (SIGY): material weakness history

Sigyn Therapeutics, Inc. reported ineffective internal control over financial reporting because of a material weakness in 19 filings since Apr 6, 2021. The latest was its 10-Q for the period ended Sep 30, 2025.

Ctrl Worx Watch List™ status

Stopped filing
4.9 yearsopen when the Clock stopped, since at least Dec 31, 2020
10-Q, Nov 14, 2025latest filing that reports the weakness. Read it on SEC EDGAR

It filed a Form 15 to stop reporting after its last report. The Clock stopped at that report.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #11172

Filings with a weakness19
First in our dataApr 6, 2021
AuditorKreit & Chiu CPA LLP

Causes the company named

Segregation of duties · 19Entity-level and governance · 19Accounting expertise and resources · 5ITGC: general · 3

Inadequate entity-level controls, risk assessment, system controls, and segregation of duties including officer expense approval.

What the latest filing says

Based on such evaluation, management identified deficiencies that were determined to be a material weakness. Management’s Report on Internal Controls over Financial Reporting The Company’s management is responsible for establishing and maintaining effective internal control over financial reporting (as defined in Rule 13a-l5(f) of the Securities Exchange Act). Management assessed the effectiveness of the Company’s internal control over financial reporting as of September 30, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) (2013). Based on that assessment, management believes that, as of September 30, 2025, the Company’s internal control over financial reporting was ineffective based on the COSO criteria, due to the following material weaknesses listed below. The specific material weaknesses identified by the company’s management as of end of the period covered by this report include the following: ● we have not performed a risk assessment and mapped our processes [...]

From the controls section of the 10-Q filed Nov 14, 2025. Read the full filing on SEC EDGAR.

Company response: Sigyn Therapeutics, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
Nov 14, 202510-QSep 30, 2025Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Sep 5, 202510-QJun 30, 2025Not effectiveSegregation of duties; ITGC: general; Entity-level and governanceEDGAR
May 20, 202510-QMar 31, 2025Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Apr 15, 202510-KDec 31, 2024Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Nov 19, 202410-QSep 30, 2024Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Aug 19, 202410-QJun 30, 2024Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Feb 20, 202410-KDec 31, 2023Not effectiveSegregation of duties; Accounting expertise and resources; Entity-level and governanceEDGAR
Nov 14, 202310-QSep 30, 2023Not effectiveSegregation of duties; Accounting expertise and resources; ITGC: general; Entity-level and governanceEDGAR
Aug 14, 202310-QJun 30, 2023Not effectiveSegregation of duties; Accounting expertise and resources; Entity-level and governanceEDGAR
May 15, 202310-QMar 31, 2023Not effectiveSegregation of duties; Accounting expertise and resources; Entity-level and governanceEDGAR
Mar 31, 202310-KDec 31, 2022Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Nov 14, 202210-QSep 30, 2022Not effectiveSegregation of duties; Accounting expertise and resources; Entity-level and governanceEDGAR
Aug 15, 202210-QJun 30, 2022Not effectiveSegregation of duties; Entity-level and governanceEDGAR
May 13, 202210-QMar 31, 2022Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Mar 21, 202210-KDec 31, 2021Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Nov 12, 202110-QSep 30, 2021Not effectiveSegregation of duties; Entity-level and governanceEDGAR
Aug 16, 202110-QJun 30, 2021Not effectiveSegregation of duties; Entity-level and governanceEDGAR
May 17, 202110-QMar 31, 2021Not effectiveSegregation of duties; ITGC: general; Entity-level and governanceEDGAR
Apr 6, 202110-KDec 31, 2020Not effectiveSegregation of duties; Entity-level and governanceEDGAR

Follow SIGY for free

Get an email when Sigyn Therapeutics, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx™. The filings are the authority. Ctrl Worx is not affiliated with Sigyn Therapeutics, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.